Kiniksa Pharmaceuticals LtdNASDAQ:KNSA
- LAST PRICE18.9700
- TODAY'S CHANGE (%)0.1000 (0.5299%)
- Bid / Lots15.3900/ 3
- Ask / Lots19.4700/ 1
- Open / Previous Close18.7900 / 18.8700
- Day Range
- 52 Week Range
- Volume427,810
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KNSA |
|---|---|---|
| 09:32 ET | 3828 | 18.74 |
| 09:34 ET | 800 | 18.8 |
| 09:36 ET | 400 | 18.7175 |
| 09:38 ET | 300 | 18.71 |
| 09:39 ET | 2137 | 18.67 |
| 09:41 ET | 1750 | 18.66 |
| 09:43 ET | 1446 | 18.725 |
| 09:45 ET | 500 | 18.67 |
| 09:48 ET | 300 | 18.67 |
| 09:52 ET | 1100 | 18.725 |
| 09:54 ET | 100 | 18.66 |
| 09:56 ET | 1846 | 18.52 |
| 09:57 ET | 5887 | 18.54 |
| 10:01 ET | 2420 | 18.57 |
| 10:03 ET | 300 | 18.62 |
| 10:10 ET | 200 | 18.63 |
| 10:12 ET | 700 | 18.62 |
| 10:14 ET | 626 | 18.65 |
| 10:15 ET | 1379 | 18.73 |
| 10:21 ET | 100 | 18.72 |
| 10:24 ET | 300 | 18.71 |
| 10:26 ET | 700 | 18.71 |
| 10:28 ET | 727 | 18.71 |
| 10:30 ET | 200 | 18.7 |
| 10:32 ET | 107 | 18.7 |
| 10:33 ET | 163 | 18.721 |
| 10:35 ET | 690 | 18.71 |
| 10:39 ET | 520 | 18.73 |
| 10:42 ET | 300 | 18.75 |
| 10:46 ET | 100 | 18.79 |
| 10:48 ET | 800 | 18.8 |
| 10:50 ET | 900 | 18.87 |
| 10:51 ET | 517 | 18.94 |
| 10:53 ET | 200 | 18.91 |
| 10:55 ET | 100 | 18.95 |
| 10:57 ET | 200 | 18.95 |
| 11:06 ET | 100 | 19.015 |
| 11:08 ET | 100 | 19.005 |
| 11:11 ET | 800 | 19.1 |
| 11:13 ET | 400 | 19.115 |
| 11:15 ET | 353 | 19.1 |
| 11:26 ET | 799 | 19.04 |
| 11:27 ET | 300 | 19.05 |
| 11:29 ET | 386 | 19.05 |
| 11:33 ET | 174 | 19.04 |
| 11:42 ET | 800 | 19.03 |
| 11:45 ET | 1606 | 19 |
| 11:47 ET | 445 | 19.04 |
| 11:51 ET | 1102 | 18.96 |
| 11:56 ET | 300 | 18.98 |
| 12:02 ET | 241 | 18.95 |
| 12:05 ET | 918 | 18.9697 |
| 12:09 ET | 171 | 18.96 |
| 12:12 ET | 500 | 18.97 |
| 12:16 ET | 900 | 18.98 |
| 12:20 ET | 300 | 18.99 |
| 12:21 ET | 300 | 19 |
| 12:23 ET | 200 | 19 |
| 12:27 ET | 100 | 19.019 |
| 12:30 ET | 332 | 19.01 |
| 12:32 ET | 100 | 19.01 |
| 12:34 ET | 600 | 19 |
| 12:36 ET | 400 | 18.97 |
| 12:39 ET | 1902 | 19.01 |
| 12:43 ET | 100 | 18.985 |
| 12:48 ET | 510 | 19.015 |
| 12:50 ET | 200 | 19.03 |
| 12:52 ET | 100 | 19.04 |
| 12:59 ET | 100 | 19.03 |
| 01:03 ET | 427 | 19.05 |
| 01:10 ET | 1000 | 19.04 |
| 01:14 ET | 113 | 19.0599 |
| 01:15 ET | 900 | 19.085 |
| 01:17 ET | 100 | 19.085 |
| 01:19 ET | 717 | 19.07 |
| 01:26 ET | 200 | 19.08 |
| 01:28 ET | 200 | 19.07 |
| 01:30 ET | 1415 | 19.085 |
| 01:33 ET | 1772 | 19.07 |
| 01:44 ET | 100 | 19.04 |
| 01:48 ET | 1200 | 19.07 |
| 01:51 ET | 918 | 19.04 |
| 02:02 ET | 600 | 19.06 |
| 02:06 ET | 209 | 19.056 |
| 02:08 ET | 100 | 19.055 |
| 02:09 ET | 467 | 19.06 |
| 02:11 ET | 100 | 19.069 |
| 02:15 ET | 3801 | 19.1 |
| 02:18 ET | 100 | 19.11 |
| 02:20 ET | 200 | 19.09 |
| 02:22 ET | 403 | 19.1 |
| 02:26 ET | 100 | 19.11 |
| 02:27 ET | 900 | 19.11 |
| 02:29 ET | 206 | 19.11 |
| 02:31 ET | 1500 | 19.08 |
| 02:33 ET | 100 | 19.03 |
| 02:36 ET | 511 | 19.02 |
| 02:38 ET | 300 | 19.02 |
| 02:40 ET | 610 | 18.99 |
| 02:42 ET | 400 | 18.94 |
| 02:45 ET | 200 | 18.95 |
| 02:47 ET | 843 | 18.92 |
| 02:49 ET | 1741 | 18.92 |
| 02:51 ET | 100 | 18.93 |
| 02:54 ET | 100 | 18.94 |
| 03:00 ET | 510 | 18.92 |
| 03:02 ET | 516 | 18.89 |
| 03:03 ET | 213 | 18.89 |
| 03:05 ET | 779 | 18.9 |
| 03:07 ET | 101 | 18.9 |
| 03:20 ET | 100 | 18.89 |
| 03:21 ET | 100 | 18.9 |
| 03:23 ET | 100 | 18.89 |
| 03:25 ET | 2015 | 18.91 |
| 03:32 ET | 700 | 18.92 |
| 03:34 ET | 2314 | 18.87 |
| 03:36 ET | 2036 | 18.86 |
| 03:38 ET | 944 | 18.87 |
| 03:39 ET | 1300 | 18.9 |
| 03:41 ET | 801 | 18.88 |
| 03:43 ET | 596 | 18.88 |
| 03:45 ET | 636 | 18.86 |
| 03:48 ET | 400 | 18.865 |
| 03:50 ET | 6442 | 18.89 |
| 03:52 ET | 3102 | 18.937 |
| 03:54 ET | 881 | 18.93 |
| 03:56 ET | 9309 | 18.97 |
| 03:57 ET | 3230 | 18.98 |
| 03:59 ET | 162419 | 18.97 |
Yesterday
Kiniksa Pharmaceuticals Partners with NHL Hall-of-Famer Henrik Lundqvist to Raise Awareness of Recurrent Pericarditis, from 8:00AM ET on Monday Jun 24, 2024 by Dow Jones
8:00AM ET on Monday Jun 24, 2024 by Dow Jones
Jun 17, 2024
Kiniksa Pharmaceuticals Sponsors American Heart Association's Addressing Recurrent Pericarditis Initiative, from 8:30AM ET on Monday Jun 17, 2024 by Dow Jones
8:30AM ET on Monday Jun 17, 2024 by Dow Jones
Jun 4, 2024
Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference, from 4:01PM ET on Tuesday Jun 04, 2024 by Dow Jones
4:01PM ET on Tuesday Jun 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kiniksa Pharmaceuticals Ltd | 1.3B | 222.7x | --- |
Dynavax Technologies Corp | 1.5B | 224.4x | --- |
BioCryst Pharmaceuticals Inc | 1.3B | -5.7x | --- |
Zai Lab Ltd | 1.8B | -5.3x | --- |
Maravai LifeSciences Holdings Inc | 1.8B | -6.9x | --- |
MannKind Corp | 1.5B | 223.6x | --- |
Company Information
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Contact Information
- Headquarters
- Clarendon House, 2 Church StreetHAMILTON, Bermuda HM11
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Sanjiv Patel
- Chief Financial Officer, Senior Vice President
- Mark Ragosa
- Chief Operating Officer, Senior Vice President
- Eben Tessari
- Senior Vice President, Chief Commercial Officer
- Ross Moat
- Senior Vice President, Chief Medical Officer
- John Paolini
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.3B |
|---|---|
Revenue (TTM) | $301.8M |
Shares Outstanding | 70.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.38 |
EPS | $0.09 |
Book Value | $6.23 |
P/E Ratio | 222.7x |
Price/Sales (TTM) | 4.4 |
Price/Cash Flow (TTM) | 123.3x |
Operating Margin | -10.12% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
